CYTOSORBENTS CORPORATION (CTSO) Net margin 2016–2025
CYTOSORBENTS CORPORATION (CTSO) net profit margin by fiscal year — reported net income divided by reported revenue.
-22.1%FY2025 · since FY2016: -123.5% → -22.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -22.1% | +36.1 pp |
| FY2024 | -58.2% | +35.9 pp |
| FY2023 | -94.1% | +0.5 pp |
| FY2022 | -94.6% | -37.7 pp |
| FY2021 | -56.9% | -37.8 pp |
| FY2020 | -19.1% | +58.1 pp |
| FY2019 | -77.2% | -0.7 pp |
| FY2018 | -76.5% | -20.6 pp |
| FY2017 | -55.8% | +67.6 pp |
| FY2016 | -123.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTSO financial trends
CTSO RevenueCTSO Net incomeCTSO Gross profitCTSO Gross marginCTSO Operating incomeCTSO Operating marginCTSO Operating cash flowCTSO Free cash flowCTSO Capital expendituresCTSO Return on equityCTSO Stock buybacksCTSO Dividends paidCTSO Total assetsCTSO Total liabilitiesCTSO Shareholders’ equityCTSO overview →